Biotech News
Belite Bio Secures $15 Million in Direct Offering with Healthcare Investor
Belite Bio, Inc., a clinical-stage biopharmaceutical company focused on treatments for degenerative retinal diseases, has announced a direct offering agreement with a fundamental healthcare investor. The transaction includes the sale of 258,309 American Depositary Shares (ADSs) and warrants to purchase
6 February 2025